

# Peripheral T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2023

<https://marketpublishers.com/r/PD352DD05E1EN.html>

Date: November 2017

Pages: 242

Price: US\$ 6,950.00 (Single User License)

ID: PD352DD05E1EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's 'Peripheral T-Cell Lymphoma (PTCL) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025' report provides provides the comprehensive insights on the competitive landscape and market of Peripheral T-Cell Lymphoma (PTCL).

The report covers an overview of the Peripheral T-Cell Lymphoma along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy, United Kingdom) and Japan. The Report provides a comprehensive review of the unmet medical needs of the disease, market trends, drivers and market barriers.

The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous Squamous Cell Carcinoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.

The Report covers detailed historical and forecasted epidemiology of Peripheral T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Anaplastic T Cell Lymphoma, AngioImmunoblastic T Cell Lymphoma, NK/T Cell Lymphoma and others), as well as stages of the disease. According to DelveInsight, the

incident cases of Peripheral T-Cell Lymphoma are expected to reach up to 24,630 by the end of 2025 at a CAGR of XX% from 2013 to 2025. High incident cases were observed in the United States as compared to EU5 and Japan.

The Report covers the therapeutics market revenue, treatment practice/algorithm and detailed market size forecast of Peripheral T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. United States contributes the major share of Peripheral T-Cell Lymphoma market as compared to EU5 countries and Japan.

Market is mainly driven by Beleodaq (Spectrum Pharmaceuticals, Inc.), Istodax (Celgene Corporation), Poteligeo (Kyowa Hakko Kirin Co., Ltd. and Folutyn (Spectrum Pharmaceuticals) being approved for the treatment of Peripheral T-Cell Lymphoma.

The therapeutic market of Peripheral T-Cell Lymphoma in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of 8.3% for the forecasted period i.e., 2013-2025.

## **KEY COVERAGE AND BENEFITS:**

The report will help in developing business strategies by understanding the trends shaping and driving the global Peripheral T-Cell Lymphoma market.

Overview of the Global pipeline scenario for global Peripheral T-Cell Lymphoma, products and associated companies information

Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities

Organize sales and marketing efforts by identifying the best opportunities for Peripheral T-Cell Lymphoma in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides historical as well as forecasted epidemiology of Peripheral T-Cell Lymphoma in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.

To understand the future market competition in the global Peripheral T-Cell

Lymphoma market and Insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

The Report also covers the detailed global historical and forecasted Peripheral T-Cell Lymphoma market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2013-2025.

## Contents

- Report Introduction
- Peripheral T-Cell Lymphoma (PTCL) Market Overview at a Glance
- Global Market Size of PTCL in 2016
- Global Market Size of PTCL in 2025
- Overview
- Subtypes of Peripheral T cell lymphoma
- Nodal Peripheral T cell lymphomas
- Extranodal Peripheral T Cell Lymphomas
- Cutaneous- Peripheral T Cell Lymphomas
- Leukemic- Peripheral T Cell Lymphomas
- Pathophysiology
- Staging
- Diagnosis
- Peripheral T-Cell Lymphoma (PTCL) Geography wise Incident Cases
- 7MM Incident PTCL Cases in 2016
- 7MM Incident PTCL Cases in 2025
- Epidemiology and Patient Population
- Key Points
- United States
- Assumptions and Rationale
- Incident Cases of PTCL in United States
- Stage wise PTCL Cases in United States
- Common Types of PTCL in United States
- Europe
- Assumptions and Rationale
- Germany
- Incident Cases of PTCL in Germany
- Stage wise PTCL Cases in Germany
- Common Types of PTCL Cases in Germany
- Italy
- Incident Cases of PTCL in Italy
- Stage wise PTCL Cases in Italy
- Common Types of PTCL Cases in Italy
- Spain
- Incident Cases of PTCL in Spain
- Stage wise PTCL Cases in Spain
- Common Types of PTCL Cases in Spain

## France

Incident Cases of PTCL in France

Stage wise PTCL Cases in France

Common Types of PTCL Cases in France

## United Kingdom

Incident Cases of PTCL in United Kingdom

Stage wise PTCL Cases in United Kingdom

Common Types of PTCL Cases in United Kingdom

## Japan

Assumptions and Rationale

Incident Cases of PTCL in Japan

Stage wise PTCL Cases in Japan

Common Types of PTCL Cases in Japan

Treatment Algorithm

## United States

## Europe

Unmet Needs

Marketed Drugs

Beleodaq (Belinostat): Onxeo S.A.

Drug Description

Mechanism of Action

Advantages & Disadvantages

Safety and Efficacy of Beleodaq

Product Profile

Istodax (Romidepsin): Celgene Corporation

Drug Description

Mechanism of Action

Advantages & Disadvantages

Safety and Efficacy of Istodax

Product Profile

Folotyn (Pralatrexate): Spectrum Pharmaceuticals

Drug Description

Mechanism of Action

Advantages & Disadvantages

Safety and Efficacy of Folotyn

Product Profile

Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.

Drug Description

Mechanism of Action

Advantages & Disadvantages  
Safety and Efficacy of Poteligeo  
Product Profile  
Adcetris (Brentuximab vedotin): Seattle Genetics  
Drug Description  
Mechanism of Action  
Advantages & Disadvantages  
Safety and Efficacy of Adcetris  
Product Profile  
Rituxan (MabThera): Genentech  
Drug Description  
Mechanism of Action  
Advantages & Disadvantages  
Safety and Efficacy of Rituxan  
Product Profile  
Emerging Therapies  
Phase III  
Brentuximab vedotin: Seattle Genetics  
Advantages & Disadvantages  
Product Profile  
Clinical Development  
Clinical Pipeline Activity  
Ongoing Trials Information  
Clinical Trial by Phase  
Masitinib: AB Science SA  
Advantages & Disadvantages  
Product Profile  
Clinical Development  
Clinical Pipeline Activity  
Ongoing Trials Information  
Clinical Trial by Phase  
Phase II  
Darinaparsin: Solasia Pharma  
Advantages & Disadvantages  
Product Profile  
Clinical Development  
Clinical Pipeline Activity  
Ongoing Trials Information  
Clinical Trial by Phase

Fenretinide: CerRx, Inc  
Advantages & Disadvantages  
Product Profile  
Clinical Development  
Clinical Pipeline Activity  
Ongoing Trials Information  
Clinical Trial by Phase  
Denileukin diftitox: Eisai Co Ltd  
Advantages & Disadvantages  
Product Profile  
Clinical Development  
Clinical Pipeline Activity  
Ongoing Trials Information  
Clinical Trial by Phase  
Lenalidomide: Celgene Corporation  
Advantages & Disadvantages  
Product Profile  
Clinical Development  
Clinical Pipeline Activity  
Ongoing Trials Information  
Clinical Trial by Phase  
Market Size  
Global PTCL Market Analysis  
Overview of Global PTCL Market (2013-2025)  
Total 7MM PTCL Market Analysis  
Overview of Total PTCL Market (2013-2025)  
PTCL Region wise Market Analysis  
Region wise Market Size (2016)  
Region wise Market Size (2025)  
7MM PTCL: Country-Wise Market Analysis  
Overview on Total PTCL Market (2016)  
Overview on Total PTCL Market (2025)  
Global PTCL: Market Analysis  
United States Market Size  
Europe Market Size  
Germany Market Size  
France Market Size  
United Kingdom Market Size  
Spain Market Size

Italy Market Size  
Japan Market Size  
Market Drivers  
Market Barriers  
Appendix  
Report Methodology  
Consulting Services  
Disclaimer  
About DelveInsight



## List Of Tables

### LIST OF TABLES

Table 1: Incident Cases of PTCL in United States (2013-2025)
Table 2: Stage wise number of cases in United States (2016)
Table 3: Common Types of cases in United States (2016)
Table 4: Incident Cases of PTCL in Germany (2013-2025)
Table 5: Stage wise number of cases in Germany (2016)
Table 6: Common Types of cases in Germany (2016)
Table 7: Incident Cases of PTCL in Italy (2013-2025)
Table 8: Stage wise number of cases in Italy (2016)
Table 9: Common Types of cases in Italy (2016)
Table 10: Incident Cases of PTCL in Spain (2013-2025)
Table 11: Stage wise number of cases in Spain (2016)
Table 12: Common Types of cases in Spain (2016)
Table 13: Incident Cases of PTCL in France (2013-2025)
Table 14: Stage wise number of cases in France (2016)
Table 15: Common Types of cases in France (2016)
Table 16: Incident Cases of PTCL in United Kingdom (2013-2025)
Table 17: Stage wise number of cases in United Kingdom (2016)
Table 18: Common Types of cases in United Kingdom (2016)
Table 19: Incident Cases of PTCL in Japan (2013-2025)
Table 20: Stage wise number of cases in Japan (2016)
Table 21: Common Types of cases in Japan (2016)
Table 22: List of Marketed Drugs for Peripheral T Cell Lymphoma
Table 23: List of Emerging therapies for Peripheral T- Cell Lymphoma
Table 24: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Table 25: Clinical Trials by Trial status, 2017
Table 26: Masitinib, Clinical Trials by Zone, 2017
Table 27: Clinical Trials by Trial status, 2017
Table 28: Darinaparsin, Clinical Trials by Zone, 2017
Table 29: Clinical Trials by Trial status, 2017
Table 30: Fenretinide, Clinical Trials by Zone, 2017
Table 31: Clinical Trials by Trial status, 2017
Table 32: Denileukin diftitox, Clinical Trials by Zone, 2017
Table 33: Clinical Trials by Trial status, 2017
Table 34: Lenalidomide, Clinical Trials by Zone, 2017
Table 35: Clinical Trials by Trial status, 2017

Table 36: Global Market Size of PTCL in USD Million, (2013-2025)

Table 37: Market Size of PTCL-7MM in USD Million (2013-2025)

Table 38: Total PTCL, Market Revenue (2016) as per the 7MM

Table 39: Total PTCL, Market Revenue (2025) as per the 7MM

Table 40: Market Size of PTCL-United States in USD Million (2013-2025)

Table 41: Market Size of PTCL-Germany in USD Million (2013-2025)

Table 42: Market Size of PTCL-France in USD Million (2013-2025)

Table 43: Market Size of PTCL-United Kingdom in USD Million (2013-2025)

Table 44: Market Size of PTCL-Spain in USD Million (2013-2025)

Table 45: Market Size of PTCL-Italy in USD Million (2013-2025)

Table 46: Market Size of PTCL-Japan in USD Million (2013-2025)

## List Of Figures

### LIST OF FIGURES

- Figure 1: Classification of Peripheral T- Cell Lymphoma
- Figure 2: T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
- Figure 3: Incident Cases of PTCL in United States (2013-2025)
- Figure 4: Stage wise PTCL cases in United States (2013-2025)
- Figure 5: Common types of PTCL in United States (2013-2025)
- Figure 6: Incident Cases of PTCL in Germany (2013-2025)
- Figure 7: Stage wise PTCL cases in Germany (2013-2025)
- Figure 8: Common types of PTCL in Germany (2013-2025)
- Figure 9: Incident Cases of PTCL in Italy (2013-2025)
- Figure 10: Stage wise PTCL cases in Italy (2013-2025)
- Figure 11: Common types of PTCL in Italy (2013-2025)
- Figure 12: Incident Cases of PTCL in Spain (2013-2025)
- Figure 13: Stage wise PTCL cases in Spain (2013-2025)
- Figure 14: Common types of PTCL in Spain (2013-2025)
- Figure 15: Incident Cases of PTCL in France (2013-2025)
- Figure 16: Stage wise PTCL cases in France (2013-2025)
- Figure 17: Common types of PTCL in France (2013-2025)
- Figure 18: Incident Cases of PTCL in United Kingdom (2013-2025)
- Figure 19: Stage wise PTCL in United Kingdom (2013-2025)
- Figure 20: Common types of PTCL in United Kingdom (2013-2025)
- Figure 21: Incident Cases of PTCL in Japan (2013-2025)
- Figure 22: Stage wise PTCL cases in Japan (2013-2025)
- Figure 23: Common Types of PTCL in Japan (2013-2025)
- Figure 24: First Line of therapy for PTCL -NOS
- Figure 25: Second Line of therapy for PTCL –NOS with Stem cell transplant
- Figure 26: First Line of therapy for ALCL, ALK+
- Figure 27: Second Line of therapy for ALCL- ALK+ with Stem cell transplant
- Figure 28: First Line of therapy for ALCL, ALK-
- Figure 29: Second Line of therapy for ALCL- ALK- with Stem cell transplant
- Figure 30: First Line of therapy for AICL
- Figure 31: Second Line of therapy for AICL with Stem cell transplant
- Figure 32: First Line of therapy for Enteropathy associated TCL
- Figure 33: Second Line of therapy for enteropathy associated T cell lymphoma with stem cell transplantation

Figure 34: Treatment for Nodal and Extranodal Peripheral T cell Lymphomas

Figure 35: Treatment for relapsed/ refractory Nodal and Extranodal Peripheral T cell Lymphomas

Figure 36: Brentuximab vedotin, Clinical Trials by Zone (%), 2017

Figure 37: Brentuximab Vedotin, Clinical Trials by Trial status (%), 2017

Figure 38: Masitinib, Clinical Trials by Zone (%), 2017

Figure 39: Masatinib, Clinical Trials by Trial status (%), 2017

Figure 40: Darinaparsin, Clinical Trials by Zone (%), 2017

Figure 41: Darinaparsin, Clinical Trials by Trial status (%), 2017

Figure 42: Fenretinide, Clinical Trials by Zone (%), 2017

Figure 43: Fenretinide, Clinical Trials by Trial status (%), 2017

Figure 44: Denileukin diftitox, Clinical Trials by Zone (%), 2017

Figure 45: Denileukin diftitox, Clinical Trials by Trial status (%), 2017

Figure 46: Lenalidomide, Clinical Trials by Zone (%), 2017

Figure 47: Lenalidomide, Clinical Trials by Trial status (%), 2017

Figure 48: Global Market Size of PTCL in USD Millions (2013-2025)

Figure 49: Market Size of PTCL- 7MM in USD Millions (2013-2025)

Figure 50: Market Size of PTCL Country-wise in USD Millions (2016)

Figure 51: Market Size of PTCL Country-wise in USD Millions (2025)

Figure 52: Market Size of PTCL in United States in USD Millions (2013-2025)

Figure 53: Market Size of PTCL in Germany in USD Millions (2013-2025)

Figure 54: Market Size of PTCL in France in USD Millions (2013-2025)

Figure 55: Market Size of PTCL in United Kingdom in USD Millions (2013-2025)

Figure 56: Market Size of PTCL in Spain in USD Millions (2013-2025)

Figure 57: Market Size of PTCL in Italy in USD Millions (2013-2025)

Figure 58: Market Size of PTCL in Japan in USD Millions (2013-2025)

## I would like to order

Product name: Peripheral T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2023

Product link: <https://marketpublishers.com/r/PD352DD05E1EN.html>

Price: US\$ 6,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD352DD05E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

